Novartis Q3 2024 Adj. EPS $2.06 Beats $1.96 Estimate, Sales $12.823B Beat $12.764B Estimate
Portfolio Pulse from Benzinga Newsdesk
Novartis reported Q3 2024 earnings of $2.06 per share, surpassing the $1.96 estimate, and sales of $12.823 billion, exceeding the $12.764 billion estimate. This marks an 18.39% increase in EPS and an 8.85% increase in sales compared to the previous year.
October 29, 2024 | 6:22 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Novartis reported better-than-expected Q3 2024 earnings and sales, with EPS of $2.06 beating estimates by 5.1% and sales of $12.823 billion exceeding expectations. This reflects strong financial performance and growth compared to the previous year.
Novartis' Q3 2024 earnings and sales both exceeded analyst expectations, indicating strong financial performance. The EPS beat by 5.1% and sales beat by 0.46% suggest positive investor sentiment and potential upward movement in stock price.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100